Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

被引：2

作者：

Graff, J. N. ^{[1
]}

Burotto, M. ^{[2
]}

Fong, P. C. ^{[3
]}

Pook, D. ^{[4
]}

Zurawski, B. ^{[5
]}

Kopp, R. Manneh ^{[6
]}

Salinas, J. E. ^{[7
]}

Bylow, K. ^{[8
,9
]}

Kramer, G. ^{[10
]}

Ratta, R. ^{[11
]}

Kwiatkowski, M. ^{[12
]}

Retz, M. ^{[13
]}

Kwak, C. ^{[14
]}

Arija, J. A. Arranz ^{[15
]}

Gurney, H. P. ^{[16
]}

Matsubara, N. ^{[17
]}

Liang, L. W. ^{[18
]}

Todoric, J. ^{[18
]}

Imai, K. ^{[18
]}

Stenzl, A. ^{[19
]}

机构：

[1] OHSU Oregon Hlth Sci Univ, Hematol Oncol Dept, Portland, OR USA

[2] Bradford Hill Clin Ctr, Med Oncol Dept, Recoleta, Chile

[3] Auckland City Hosp, Med Oncol Dept, Auckland, New Zealand

[4] Monash Hlth, Monash Med Ctr, Oncol Dept, Clayton, Vic, Australia

[5] Prof Franciszek Lukaszczyk Oncol Ctr, Oncol, Bydgoszcz, Poland

[6] Sociedad Oncol & Hematol Cesar, Dept Med Oncol, Valledupar, Colombia

[7] Hosp Prov Cordoba, Oncol, Cordoba, Spain

[8] Froedtert Hosp, Med Oncol, Milwaukee, WI USA

[9] Med Coll Wisconsin, Milwaukee, WI USA

[10] Med Univ Vienna, Urol, Vienna, Austria

[11] Hop Foch, Dept Med Oncol, Suresnes, France

[12] Szpital Wojewodzki Mikolaja Kopernika, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[13] Tech Univ Munich, Rechts Isar Med Ctr, Urol, Munich, Germany

[14] Seoul Natl Univ, Coll Med, Urol, Yeongeon Med Campus, Seoul, South Korea

[15] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[16] Macquarie Univ, Med Oncol, Fac Med Hlth & Human Sci, Sydney, NSW, Australia

[17] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Chiba, Japan

[18] Merck Co Inc, Oncol, Rahway, NJ USA

[19] Univ Tubingen, Urol Dept, Crona Kliniken, Tubingen, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2721

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1771MO

引用

页码：S957 / S957

页数：1

共 50 条

[31] KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
Omlin, A. G.
Graff, J. N.
Hoimes, C. J.
Tagawa, S. T.
Hwang, C.
Kilari, D.
Ten Tije, A. J.
McDermott, R.
Vaishampayan, U. N.
Elliott, T.
Gerritsen, W. R.
Wu, H.
Kim, J.
Schloss, C.
de Bono, J. S.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2020, 31 : S514 - S515
[32] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.
Gratzke, Christian
Burgents, Joseph E.
Niu, Cuizhen
Poehlein, Christian Heinrich
Drak, Charles G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
Augustin, Marinela
Laguerre, Brigitte
Baldini, Capucine
Zedan, Ahmed H.
Gonzalez-Billalabeitia, Enrique
Fong, Peter C. C.
Zukov, Ruslan
Hammerer, Peter
Prentice, Mark
Shore, Neal D.
Necchi, Andrea
Todenhoefer, Tilman
Kessler, Elizabeth R.
Kose, Fatih
Gurney, Howard
Valderrama, Begona Perez
Zhu, Pengfei
Imai, Kentaro
Liu, Yingjie
McDermott, Raymond S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
[35] Second-/Third-Line Therapy after Failure of Next-Generation-Hormone Therapy (NHA) and possibly Second-Line Therapy with Abiraterone for Patients with metastatic Prostate Cancer (mCRPC) Randomized, double-blind Phase-III Study of Pembrolizumab (MK-3475) and plus Enzalutamide Combination versus Placebo and Enzalutamide Combination in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) (KEYNOTE-641) AP 107/19 of the AUO
Rexer, H.
Stenzl, A.
Boegemann, M.
AKTUELLE UROLOGIE, 2021, 52 (03) : 218 - 219
[36] Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.
Graff, Julie Nicole
Alumkal, Joshi J.
Thompson, Reid F.
Moran, Amy
Thomas, George V.
Wood, Mary A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Agarwal, N.
Azad, A. A.
Mateo, J.
Shore, N. D.
Chakrabarti, J.
Chen, H-C.
Lanzalone, S.
Niyazov, A.
Saad, F.
ANNALS OF ONCOLOGY, 2021, 32 : S672 - S673
[38] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
Gratzke, Christian
Niu Cuizhen
Poehlein, Christian Heinrich
Burgents, Joseph E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[39] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Piulats, Josep M.
Sridhar, Srikala S.
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[40] TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
Agarwal, Neeraj
Azad, Arun
Shore, Neal D.
Carles, Joan
Fay, Andre P.
Dunshee, Curtis
Karsh, Lawrence Ivan
Paccagnella, Maria Luisa
Di Santo, Nicola
Elmeliegy, Mohamed
Lin, Xun
Niyazov, Alexander
Czibere, Akos
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →